{"id":"W4393164331","doi":"10.1007/s40257-024-00853-4","title":"Early and Sustained Improvements in Symptoms and Quality of Life with Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: 52-Week Results from Two Phase III Randomized Clinical Trials (Measure Up 1 and Measure Up 2)","year":2024,"lang":"en","type":"article","venue":"American Journal of Clinical Dermatology","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"ca_institutions":"Probity Medical Research; SKiN Health; Queen's University","funders":"National Center for Advancing Translational Sciences; AbbVie","keywords":"Medicine; Atopic dermatitis; Randomized controlled trial; Quality of life (healthcare); Clinical trial; Pharmacotherapy; Pediatrics; Internal medicine; Dermatology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001794767,0.0004987652,0.001650654,0.0002345575,0.0002414647,0.0006646548,0.0003123066,0.0006205687,0.001127287],"category_scores_gemma":[0.001148885,0.0002700349,0.001382312,0.0003178674,0.000327515,0.0004679865,0.0002828109,0.00146295,0.0001312698],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004682278,"about_ca_system_score_gemma":0.0007644224,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006804554,"about_ca_topic_score_gemma":0.002686435,"domain_scores_codex":[0.9993673,0.0002814951,0.00006455901,0.00008340188,0.0000983576,0.0001048441],"domain_scores_gemma":[0.9994087,0.0001150341,0.0002018691,0.00003466033,0.00005465683,0.0001850871],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6331574,0.03392443,0.03773599,0.003010655,0.005108263,0.0002451997,0.0003660837,0.00143663,0.02723954,0.0001732681,0.002907396,0.2546952],"study_design_scores_gemma":[0.3782523,0.4130045,0.1948522,0.0002785959,0.003626604,0.0004195184,0.0001683148,0.001309444,0.004794678,0.0001351292,0.003103457,0.00005530943],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9924522,0.005400273,0.0001927814,0.0001662409,0.00003906825,0.0007091635,0.0004310485,0.00002506217,0.0005842223],"genre_scores_gemma":[0.9950229,0.002361917,0.0006184444,0.0003443867,0.00005230226,0.0007367653,0.0005584817,0.000005308566,0.0002995616],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001794767,"threshold_uncertainty_score":0.009491742,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05139782894144093,"score_gpt":0.4066843368383661,"score_spread":0.3552865078969252,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}